1. Home
  2. PCB vs RZLT Comparison

PCB vs RZLT Comparison

Compare PCB & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

HOLD

Current Price

$27.73

Market Cap

410.1M

Sector

Finance

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$5.13

Market Cap

420.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
RZLT
Founded
2003
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.1M
420.8M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
PCB
RZLT
Price
$27.73
$5.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$25.50
$9.67
AVG Volume (30 Days)
36.2K
1.1M
Earning Date
04-23-2026
05-13-2026
Dividend Yield
3.65%
N/A
EPS Growth
48.28
26.32
EPS
1.47
N/A
Revenue
$2,899,000.00
N/A
Revenue This Year
$13.73
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$18.83
N/A
Revenue Growth
4.51
N/A
52 Week Low
$19.70
$1.07
52 Week High
$30.84
$11.46

Technical Indicators

Market Signals
Indicator
PCB
RZLT
Relative Strength Index (RSI) 44.70 61.57
Support Level $27.31 $4.48
Resistance Level $29.04 $5.36
Average True Range (ATR) 0.72 0.28
MACD -0.08 0.02
Stochastic Oscillator 22.84 58.16

Price Performance

Historical Comparison
PCB
RZLT

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: